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Application of underdamped Langevin dynamics simulations for the study of diffusion
from a drug-eluting stent
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We use a one-dimensional two layer model with a semi-permeable membrane to study the diffusion
of a therapeutic drug delivered from a drug-eluting stent (DES). The rate of drug transfer from the
stent coating to the arterial wall is calculated by using underdamped Langevin dynamics simulations.
Our results reveal that the membrane has virtually no delay effect on the rate of delivery from the
DES. The work demonstrates the great potential of underdamped Langevin dynamics simulations
as an easy to implement, efficient, method for solving complicated diffusion problems in systems
with a spatially-dependent diffusion coefficient.
I. INTRODUCTION
Arterial stents are indispensible in the treatment of
coronary artery disease (CAD) and more specifically
stenosis, the abnormal narrowing of blood vessels [1].
These stents are frequently implanted in arteries where
blood flow has become precariously impeded. In recent
decades, they have revolutionized the treatment of steno-
sis by providing a safer alternative to coronary surgery.
In addition to diminishing the risk of major surgery com-
plications, stents also facilitate recovery and avoid ad-
ministering general anesthesia to patients [2]. However,
arterial stents have only been able to reduce the instances
of recurring stenosis, or restenosis, to 20-30%, compared
to 30-40% in coronary surgery [3].
In an effort to further curtail these rates, drug-eluting
stents (DES) were introduced. A DES is a stent
that uses programmed pharmacokinetics to release anti-
proliferative pharmaceuticals into the arterial wall. It
is comprised of a metallic strut coated with a poly-
meric matrix or gel that encapsulates the therapeutic
drug [4]. The drug reduces smooth muscle cell growth
and prevents an inflammatory response - two predomi-
nant causes of in-stent-restenosis and neo-intima prolif-
eration [4]. Stents coated in anti-proliferative agents have
mitigated instances of restenosis to roughly 5% in clinical
trials and are FDA approved [5].
Understanding the rate at which drugs are transported
through the arterial tissue is crucial for stent design, and
as such has been studied extensively [6–33]. It has been
identified that the major mechanism of drug transfer
from the coating is diffusion through the arterial wall [34].
Thus, advective forces arising, e.g., from blood circula-
tion in the arteries have been ignored in many models.
The simplest model describing the system is based on
the solution of a diffusion equation in a two-layer one-
dimensional system. One-dimensional models represent a
mathematical idealization of the three-dimensional stent
geometry; nevertheless, they dominate the theoretical lit-
erature on the subject because the drug release is pre-
dominately along the normal direction to the stent axis
whose dimension (the stent thickness) is much smaller
then the lateral dimension (the stent radius). More com-
plex one-dimensional models give weight to other phe-
nomena and factors such as chemical reactions between
the drug and the arterial wall [7–15], directed advection
of the drug [7–9, 12–21], cell metabolism [16, 19], and the
drug topcoat membrane permeability [6, 12, 14, 22, 23].
These phenomena and factors amend the partial differ-
ential equations (PDEs) that describe the transport of
the drug. They also modify the boundary conditions be-
tween the layers and often require the introduction of
additional layers [7, 8, 17, 20, 22, 24–27]. Some studies
consider more complex two- [15, 26, 28] and even three-
dimensional [13, 19, 22, 29, 30] geometries. The PDEs
are often solved by separation of variables, or numerically
through some kind of a discretization scheme, e.g., finite
elements, finite differences, and the marker cell method.
Noteworthy exceptions include analytical Laplace trans-
form solutions [27], Boltzmann reductions [11], and nu-
merically solved Voltera integral equations [23]. Experi-
mental data is also available [31–33], and has been used
to test and validate theoretical models.
Layered systems, where in each region the diffusion co-
efficient takes a different value, constitute a subclass of a
more general class of systems with spatially varying diffu-
sivity: D = D(x). Diffusion in such systems is described
by Fick’s second law
∂P (x, t)
∂t
= −
∂J (x, t)
∂x
=
∂
∂x
(
D (x)
∂P (x, t)
∂x
)
, (1)
where P (x, t) is the probability of being at coordinate
x at time t, and J(x, t) = −D(x)∂xP (x, t) is the prob-
ability flux. An alternative route for calculating P (x, t)
is to numerically integrate the corresponding Langevin
equation [36]
m
dv
dt
= −α(x)v + β (x (t)) , (2)
where m and v denote, respectively, the mass and ve-
locity of a diffusing particle. Langevin’s equation de-
scribes Newtonian dynamics under the action of two ef-
fective forces: friction [first term on the r.h.s. of Eq. (2)]
2and stochastic thermal noise (second term). The fric-
tion coefficient α(x) in (2) is related to the diffusivity
D(x) in (1) via Einstein’s relation α(x) = kBT/D(x)
[37, 38], where T is the temperature of the system
and kB is Boltzmann’s constant. The stochastic noise,
β, is chosen from a Gaussian distribution with zero
mean 〈β(x(t))〉 = 0, and delta-function auto-correlation
〈β(t)β(t′)〉 = 2kBTα(x(t))δ(t− t′)[38, 39]. The probabil-
ity density function (PDF) of the particle, P (x, t), can
be computed from an ensemble of simulated trajectories,
where the initial position of the particle at each trajec-
tory is chosen from the intial PDF P (x, 0).
The accuracy of the Langevin dynamics simulation
method for computing P (x, t) depends largely on the
quality of the discrete-time numerical integrator. Here
(as in previous works [40]), we use the efficient and robust
method of Grønbech-Jensen and Farago (G-JF) [35, 41]
in combination with the “inertial” convention [38, 39] for
choosing the value of α. In the absence of conservative
forces from a potential energy gradient (which is the case
discussed throughout this paper), the G-JF integrator
employs the following set of equations
xn+1 = xn + bdtvn +
bdt
2m
βn+1, (3)
vn+1 = avn +
b
m
βn+1, (4)
to advance the coordinate xn = x(tn) and velocity v
n =
v(tn) by one time step from time tn = ndt to tn+1 =
tn + dt. In the above G-JF equations (3)-(4), β
n+1 is a
Gaussian random number satisfying
〈βn〉 = 0 ;
〈
βnβl
〉
= 2αkBTdtδn,l, (5)
and the dampening coefficients of the algorithm are
b = [1 + (αdt/2m)]−1 ; a = [1− (αdt/2m)] b. (6)
Since the friction varies in space, the integrator must
be complemented with a convention for choosing the
value of α to be used in Eqs.(5) and (6) at each time
step. The ambiguity concerning the appropriate choice
of α is known in the literature as the “Itoˆ-Stratonovich
dilemma”[42–44]. Here, we use the recently proposed in-
ertial convention [38, 39] that assigns to α the value of
the spatial average of α(x) along the inertial trajectory
from xn to x˜n+1 = xn + vndt
α¯ ≡
∫ x˜n+1
xn
α(x)dx
x˜n+1 − xn
=
A(x˜n+1)−A(xn)
x˜n+1 − xn
, (7)
where A(x) is the primitive function of α(x). We have
previously demonstrated that while any reasonable con-
vention for choosing α yields the correct PDF at the limit
of infinitesimally small time step dt → 0, the inertial
convention gives very accurate results even for relatively
large time steps. This property of the inertial convention
stems from the fact that at small time scales, dt≪ m/α,
the inertial trajectory serves as the leading approxima-
tion to the actual path of the particle.
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FIG. 1: The PDF of the two-layer problem (the vertical line
at x = 0 represents the interface). Open circles and the solid
line denote, respectively, the results of the Langevin dynam-
ics simulations and the analytical solution Eq. (8) at t = 100.
Similarly, the open diamonds and the dashed line denote re-
sults for t = 1000.
II. TWO-LAYER SYSTEMS
Assuming in Eq. (1) that 0 < D(x) < ∞ (−∞ <
x < ∞), the resulting P (x, t) (for t > 0) must be a
continuous function for any initial condition. The flux
j(x, t) = −D(x)∂xP (x, t) must also be continuous if no
source or sink of probability are present in the system.
These properties of the PDF also apply to layered sys-
tems where D is piece-wise constant. In this paper, we
consider a simple one-dimensional two-layer model for a
DES. Before arriving at that model, we first consider the
simplest two-layer system, where D(x) = D1 for x < 0
and D(x) = D2 for x > 0. As just stated above, both
the PDF and the flux must be continuous, including at
x = 0, which sets the boundary conditions at the in-
terface between the layers. Assuming that a particle is
initially located at x = x0 > 0, i.e., P (x, 0) = δ(x− x0),
then the normalized (i.e., satisfying
∫∞
−∞ P (x, t)dx = 1)
solution of (1) for t > 0 is given by
P (x, t) =


A√
4piD1t
e−
(x−x1)
2
4D1t x < 0
1√
4piD2t
e
− (x−x0)
2
4D2t + B√
4piD2t
e
− (x+x0)
2
4D2t x > 0 ,
(8)
with x1 = x0
√
D1/D2, A = 2/(1 +
√
D2/D1), and B =
(1 −
√
D1/D2)/(1 +
√
D1/D2). This solution can be
interpreted as follows: For x > 0, the PDF is the outcome
of two diffusion processes associated with (i) the original
particle which has a unity weight and is located at x =
x0, and an image particle of weight B located at x =
−x0. For x < 0, the PDF represents diffusion of an
image particle of weight A = 1 − B, which is located
at x = x1. Notice that for D1 = D2, we have x1 =
x0, A = 1, B = 0, which reduces Eq. (8) to the well-
3known Gaussian solution for a particle diffusing in an
infinite space with constant diffusivity. Fig. 1 compares
the PDF (8) for D1 = 1, D2 = 0.1, and x0 = 4 (lines)
to the results of Langevin dynamics simulations based
on the above described G-JF integrator with the inertial
convention (symbols). In the simulations, we set m = 1
and kBT = 1. Thus, the friction coefficients in the layers
are given by α1 = kBT/D1 = 1 and α2 = kBT/D2 = 10.
We set the time step to dt = 0.1. For both layers, this
value of dt satisfies the condition dt ≤ 2m/α, which has
been assumed in the application of the inertial convention
for choosing α¯ (see discussion at the end of section I).
Fig. 1 depicts the PDF at t = 100 and t = 1000, based
on 2.5 × 105 trajectories. The total CPU time of the
simulations was 3 minutes on a PC. The agreement with
Eq. (8) is excellent. Interestingly, we obtained almost
identical results with dt = 4, which does not satisfy the
condition for inertial dynamics. In the latter case, the
total duration of the simulations was 5 seconds.
Two interesting limiting cases may be considered: For
D2/D1 →∞ (D2 = D, D1 → 0), we have B → 1, and
P (x, t) = 1√
4piD2t
e
− (x−x0)
2
4D2t + 1√
4piD2t
e
− (x+x0)
2
4D2t (x > 0),
(9)
which is the solution of the same problem with a reflect-
ing wall at the origin. To simulate Langevin dynamics
in the presence of a reflecting wall (located, without loss
of generality, at x = 0), we follow the trajectory of the
particle as computed by the Langevin integrator. If it
crosses the wall, i.e., when xn+1 < 0, we simply relocate
the particle at −xn+1 > 0, and reverse the velocity from
vn+1 to −vn+1. The other limiting case is D2/D1 → 0
(D2 = D, D1 →∞). Here, we have B → −1, and
P (x, t) = 1√
4piD2t
e
− (x−x0)
2
4D2t − 1√
4piD2t
e
− (x+x0)
2
4D2t (x > 0),
(10)
which is the solution of the same problem with an ab-
sorbing wall at the origin. When one simulates Langevin
dynamics with absorbing boundaries, the trajectory is
terminated when it crosses the boundary. Obviously, the
total probability is not conserved but rather diminishes
with time.
III. SEMI-PERMEABLE MEMBRANE
Drug-eluting stents include a topcoat that influences
the rate of drug release to the artery. Since the topcoat
layer is thin compared to the dimensions of the stent
and the arterial wall, it can be included in a DES two-
layer model as a semi-permeable membrane boundary
that controls the transition rate from the coating (first
layer) to the artery (second layer). Let us first discuss
the problem of diffusion across a semi-permeable mem-
brane within the general context of two-layer systems.
We denote by Pcross the probability that, within a small
time interval dt, a drug molecule arriving to the bound-
ary from the first layer crosses it to the second layer.
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FIG. 2: The PDF at t = 100 of a particle starting next to
a reflecting wall at the origin, and diffusing through a semi-
permeable membrane at x = 10 (represented by the vertical
line), with crossing probability Pcross. Squares, circles, dia-
monds and stars denote the results of the Langevin dynam-
ics simulations for Pcross = 1, 0.5, 0.25, 0.1, respectively. The
solid line shows the solution for the case with no membrane
[see Eq. (9)].
In the opposite direction (from the second layer back
to the first), the crossing probability is unity. A semi-
permeable membrane can be incorporated in Langevin
dynamics simulations of layered systems in the follow-
ing manner: Let us first consider the simpler case where
the friction coefficient α is the same on both sides of
the membrane, which is located at x = xm. We follow
the particle until it crosses the membrane (xn < xm and
xn+1 > xm). In order to decide whether the particle
should cross the boundary or be reflected from it, we
draw a random number, R, from a uniform distribution
between zero and one. We accept the new coordinate
and velocity
(
xn+1, vn+1
)
if R < Pcross (crossing), and
reverse them to
(
2xm − x
n+1,−vn+1
)
if R > Pcross (re-
flection). If α varies across the membrane, the algorithm
is only slightly more complicated: The new coordinate
and velocity (xn+1, vn+1) are computed assuming that
the friction varies in space, i.e., with the inertial conven-
tion for the average friction during the time step [Eq. (7)].
The step is accepted for R < Pcross and is changed to a
reflection step for R > Pcross. In the latter case, one
must take into account the fact that the particle has not
passed the membrane and, therefore, the friction coeffi-
cient along its trajectory remains constant. Therefore,
the new coordinate and velocity are recalculated using
the G-JF algorithm, with the already chosen value of
βn+1, but with the friction coefficient at the initial co-
ordinate xn < xm. The recalculated (x
n+1, vn+1) are
accepted if the particle has not crossed the membrane
(xn+1 < xm), and changed to
(
2xm − x
n+1,−vn+1
)
if it
has.
Fig. 2 shows simulation results for the PDF of a par-
ticle, initially located right next at a reflecting wall at
4(B)(A)
strut topcoat
coating
strut
arterial wall
arterial wall
FIG. 3: (A) A cross section of a stented artery, and (B) the
corresponding one-dimensional two-layer model for drug re-
lease from the stent to the artery.
x = 0, and diffusing in a medium with constant D = 1
that has a semi-permeable membrane at xm = 10. The
PDF at t = 100 is plotted for various values of Pcross.
The PDF is discontinuous at xm because the membrane
interferes with the diffusion rates. However, the mem-
brane is not a probability sink or source and, therefore,
the probability flux, j(x) = −D∂xP (x, t), arriving at
the membrane from left (x → xm−) is the same as the
flux leaving the membrane to the right (x → xm+).
This last feature of the PDF is visually apparent in
Fig. 2. Since the membrane (partially) blocks the drug
flow only from left to right, the probability density drops
across the membrane, i.e., P (xm−, t) > P (xm+, t). The
data in Fig. 2 suggests that the following relation holds:
Pcross = P (xm+, t)/P (xm−, t). This relation is antici-
pated from the continuity of the flux and the fact that
for each Pcross molecules crossing the membrane from
left to right, one molecule passes from right to left. For
Pcross = 1, the membrane is effectively non-existent be-
cause it does not impede the diffusion. In this limit,
P (x, t) becomes continuous at xm and is given by Eq. (9)
with x0 = 0 (solid line in Fig 2).
IV. TWO-LAYER STENT MODEL
A. The model
Fig. 3 (A) shows a cross section of a stented artery with
the struts in contact with the arterial wall. Fig. 3(B)
illustrates the mapping of the system to the simple one-
dimensional model discussed herein. The model consists
of two layers representing, respectively, the coating and
the arterial wall. The first layer (coating), which has
length L1, is bounded between the stent strut (x = −L1)
and the stent topcoat (x = 0). The former is a reflecting
boundary, while the latter is a thin semi-permeable mem-
brane. The second layer (the arterial wall) is of length
L2. It is bounded between the topcoat and the adventi-
tial side of the arterial wall (x = L2), which is modeled
as an absorbing boundary since the drug arriving at the
end of the artery is lost in the tissues adjacent to the
adventitia. The first and second layers have diffusion co-
parameter physical normalized simulation
value value value
L1 5× 10
−6 m 1 1
L2 10
−4 m 20 20
D1 10
−17 m2/s 1/700 1/700
D2 7× 10
−15 m2/s 1 1
kBT 4.3× 10
−21 J 1 1
m 1.5× 10−24 kg 6.8× 10−19 1
τ1 2.5× 10
6 s 700 700
τ2 1.4× 10
6 s 400 400
τm 3.5× 10
−18 s 9.7× 10−22 1/700
TABLE I: Model parameters and their physical (second col-
umn), normalized (third column), and simulation (fourth col-
umn) values.
efficients D1 and D2, respectively. We denote by m the
mass of a drug molecule, and use the thermal energy kBT
as the energy scale of the problem.
Typical values for the system parameters are given in
the second column of Table I in MKS units. In the third
column, the same parameters are given in normalized
units, where L1 = 1, D2 = 1, and kBT = 1. Table I
also gives the physical and normalized values of the time
scales τi = L
2
i /Di (i = 1, 2), which are the characteristic
diffusion times in each layer. Notice the interesting fea-
ture that these two time scales are of the same order of
magnitude.
B. Using a fictitious mass
Another characteristic time scale appearing in table I is
τm = mD/kBT , which is the crossover time from inertial
to diffusive Langevin dynamics. This time scale, to be
henceforth referred to as the ballistic time, is very impor-
tant from a computational perspective since Langevin dy-
namics simulations with the inertial interpretation must
be run with time step dt < τm in order to appropriately
simulate the transition statistics between the layers. In
multi-layers systems, the limit on dt is set by the most
viscous layer with the smallest diffusion coefficient and
the smallest ballistic time. Therefore, in table I, we only
give τm of the first layer. For the stent model, we have
τm ∼ 10
−18 sec, which is more than 24 orders of mag-
nitude smaller than the diffusion times τ1 and τ2. This
poses a huge computational challenge, as the aim of the
study is to measure quantities like the rate of drug trans-
fer to the bloodstream, which require simulations on time
scales comparable to τ = τ1 + τ2. This implies that each
simulated trajectory requires, at least, 1024 time-steps,
which would make the simulations prohibitively time con-
suming. More specifically, simulations of just 104 trajec-
tories would require 1013 years (!) of CPU time on a
state of the art PC.
5The key to circumvent this outstanding computational
problem is to notice that the diffusion equation (1) and
Langevin’s equation (2) yield the same long-time proba-
bility distributions if Einstein’s relationD(x)α(x) = kBT
is satisfied. The mass of the particle, which only appears
in Eq. (2), is unimportant for this relationship between
the two equations to hold. Therefore, if we are only in-
terested in obtaining the PDF at time scales comparable
to τ , we can use a fictitious mass which is much larger
than the actual mass and, thus, artificially increase the
ballistic time τm. Of course, the artificial ballistic time
must still be much smaller than the diffusion time, but
τm does not need to be negligibly smaller than τ . In the
fourth column of table I we give the normalized values
of the model parameters used in our Langevin dynamics
simulations of the DES model. The simulations values
are identical to the normalized values for Li, Di, and
kBT , but the mass in the simulations is set to unity, i.e.,
about 18 orders of magnitude larger than the actual nor-
malized mass of a drug molecule. This narrows the gap
between the ballistic time and diffusion times to 5-6 or-
ders of magnitude, and makes computationally feasible
simulations of hundreds of thousands of trajectories with
integration time-step dt≪ τm.
C. Membrane permeability
In section III we defined Pcross to be the left-to-right
crossing probability of the membrane in one time step.
Since the time step of the simulations is typically several
orders of magnitude smaller than the physical time scales
of interest (dt ≪ τ), the crossing probability Pcross will
generally be very small, which would considerably slow
down the simulations. To circumvent this problem, as
well as the problem arising from the difficulty to accu-
rately estimate the crossing probability, we replace Pcross
with a different measure for the membrane permeability
- the permeation time T . The latter can be related to
Pcross by noticing that each time the particle attempts to
cross the membrane, it has probability Pcross to cross it
and probability 1−Pcross to be reflected. Thus, the prob-
ability of passing the membrane at the k-th attempt is
Pcross(1−Pcross)
k−1, and the corresponding crossing time
(measured from the time of the first crossing attempt) is
Tk = (k − 1)∆, where ∆ is the return time between suc-
cessive crossing attempts. This argument demonstrates
that the permeation times are geometrically distributed,
with an average crossing time 〈Tk〉 = ∆(1−Pcross)/Pcross.
In reality, ∆ is obviously not fixed but, itself, follows
a certain continuous distribution. Therefore, the actual
permeation time does not follow a discrete geometric dis-
tribution, but its continuous exponential analogue
p(t) =
1
T
exp (−t/T ) , (11)
where T is the characteristic permeation time. Similarly
to its discrete counterpart 〈Tk〉, T = ∆(1−Pcross)/Pcross,
but here ∆ denotes the average time between succes-
sive attempts. To account for the delay effect of a semi-
membrane in simulations, we follow the trajectory of the
particle assuming that the membrane is fully-permeable
(i.e., as if there is no membrane present). At each cross-
ing of the membrane we draw a randomwaiting time from
the exponential distribution (11), and this delay time is
simply added to cumulative time of the dynamics.
V. RESULTS
The quantity of most interest for therapeutic applica-
tions is the rate of drug transfer from the stent coating
to the arterial tissue. This can be characterized by the
fractions Π1(t) and Π2(t) of drug present in the coat-
ing (layer 1) and the arterial wall (layer 2), respectively.
These quantities are related to the PDF via
Π1(t) =
∫ 0
−L1
P (x, t)dx, (12)
Π2(t) =
∫ L2
0
P (x, t)dx. (13)
In simulations, each trajectory is terminated upon arrival
to the arterial wall boundary, which implies that Π1(t)+
Π2(t) is a monotonic function decreasing from unity at
t = 0 to zero at t → ∞. Π1(t) and Π2(t) are simply
identified with the fraction of trajectories that at time t
arrive at some point within the coating and arterial wall
layers, respectively.
Fig. 4 shows our computational results for Π1 (dashed
curves) and Π2(t) (solid curves) as a function of the time
t. The results are based on 2.1 × 105 trajectories sim-
ulated with time step dt = 10−4 which meets the re-
quirement dt ≪ τm where τm = 1/700 is the ballistic
time (see table I). The initial coordinates of these tra-
jectories are chosen from a uniform distribution between
x = 0 and x = L1, which reflects the initial uniform dis-
tribution of the drug within the coating layer. The thin
curves in Fig. 4 depict results for the DES model without
a semi-permeable membrane, i.e., with vanishing perme-
ation time T = 0 between the layers. Not surprisingly,
Π1 decreases monotonically from 1 to 0 on a time scale
t ∼ 103 (roughly a month and a half in physical units),
which is comparable to the sum of diffusion times in the
coating and the arterial wall τ = τ1 + τ2. Π2 increases
from an initial value of 0, arrives to a maximum value for
t . 200, and then monotonically decreases to 0 at larger
times. The behavior of Π2 reflects net drug transfer from
the stent coating to the arterial wall at the beginning of
the process, followed by gradual loss of drug at longer
times, due to absorption in the tissues adjacent to the
adventitia. The thick curves in Fig. 4 depict results for
the same model but with a semi-permeable membrane
characterized by permeation time T = 10. The results
for Π1 and Π2 in this case exhibit trends similar to those
observed in the T = 0 simulations. Importantly, we again
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FIG. 4: The fraction of drug in the coating (dashed curves),
Π1, and in the arterial wall (solid curves), Π2, as a function
of time. The thin and thick curves show simulation results
for a DES with semi-permeable membranes having, respec-
tively, characteristic permeation times T = 0 (no membrane)
and T = 10. The circles represent the results of ref. [6] for
the same DES model with identical model parameters (see
footnote [45])
.
observe a decrease in the amount of drug left in the stent
as a function of time and a non-monotonic behavior of
the amount of drug found in the artery.
The open circles in Fig. 4 depict the results derived
in ref. [6] for the same DES model with identical model
parameters (see footnote [45]). These results have been
obtained by numerically solving the diffusion equation at
each layer, subject to a similar initial condition at t = 0,
and boundary conditions at x = −L1 and x = L2. At
x = 0, the author of ref. [6] imposed (i) continuity of the
flux and (ii) discontinuity in the concentration, with the
concentration jump related, via the Kedem-Katchalsky
(KK) equation [29], to the local flux and the membrane
permeability. Explicitly, in ref. [6] [Eq. (2.11) therein]
the KK equation is written in the following dimensionless
form
∂c2
∂x
= φ
(
c2 −
c1
σ
)
, (14)
where c1 and c2 are the local concentrations on the left
and right sides of the membrane, while φ and σ are
two transport coefficients depending on properties of the
two media and the permeability of the interface. This
continuum equation can be related to the particle-based
Langevin simulations in the following manner: Consider
a small time interval small dt, during which a particle
residing on the left (stent) side of the membrane has
a probability Q1 to cross the membrane, while a par-
ticle located on the right (artery) side has a crossing
probability Q2. The crossing probabilities are propor-
tional to the diffusivities of the corresponding media,
and Q1 also depends on the permeability of the mem-
brane. The flux across the membrane is given by the
difference J = v0[Q1P (0−, t)−Q2P (0+, t)], where v0 is
a proportionality coefficient with dimensionality of veloc-
ity. Since the flux is also given by J = −D1∂xP (0−, t) =
−D2∂xP (0+, t), we can also write
∂P (0+, t)
∂x
=
Q2v0
D2
[
P (0+, t)−
Q1
Q2
P (0−, t)
]
(15)
which has the same form as the KK equation for the
boundary condition (14).
The results of ref. [6] exhibit a perfect agreement with
our Langevin dynamics simulation results for T = 0. The
agreement highlights the fact (which was not sufficiently
discussed in previous studies of the model) that the DES
membrane has a nearly negligible effect on the rate of
drug flow from the stent coating to the arterial wall. The
rate of drug release from the stent can be computed by
numerical differentiation of Π1(t) (12) with respect to
time. The perfect agreement of our simulation results for
Π1(t) with ref. [6] indicates that the rate of drug release
decreases monotonically with time (see Fig. 6 therein).
VI. DISCUSSION
In this work we use underdamped Langevin dynamics
simulations for solving the diffusion equation for a sim-
ple two-layer model of a drug-eluting stent (DES). To
the best of our knowledge, this is the first attempt to de-
rive the solution of a DES model using this approach. In
fact, the application of underdamped Langevin dynamics
simulations is also highly uncommon in other engineer-
ing and natural science areas dealing with the solution of
complex diffusion equations. Much more common is the
use of finite element and finite difference methods. These
exist in a variety of forms, and the selection, design,
and implementation of a method that best fits a given
problem may be a complicated task. Langevin dynam-
ics simulations constitute an alternative approach; how-
ever, the vast majority of studies of diffusion problems
are based on simulations of the overdamped Langevin
equation which neglect the inertial term on the r.h.s. of
Eq.(2). This introduces complications stemming from
the Itoˆ-Stratonovich dilemma and the associated spuri-
ous drift. These complications can be addressed when
D(x) is a smooth function which varies only slightly dur-
ing an integration time step, but not in simulations of
layered systems where D(x) is discontinuous. In the lat-
ter case, one must introduce decision rules for crossing
the boundary between layers, even if those layers are not
separated by a membrane. A Monte-Carlo algorithm im-
plementing such types of decision rules has been recently
presented [46], but we are not aware of a similar algo-
rithm for overdamped Brownian dynamics. This extraor-
dinary problem is completely avoided in underdamped
Langevin dynamics simulations which, if run properly,
produce correct thermal diffusion between sharp inter-
faces. Accurate solutions for a wide range of diffusion
equations can be obtained by this approach with relative
7computational simplicity and accuracy, provided that one
uses a robust integration scheme (such as the G-JF inte-
grator) together with a suitable convention rule for choos-
ing the average α within a time-step of the simulations
(e.g., the “inertial” convention). The merits of the ap-
proach are nicely exemplified in Fig. 4, which exhibits
perfect agreement between the simulation results of this
paper and the predictions of ref. [6] for the same model.
The only parameter that needs to be tuned in the sim-
ulations is the mass of the diffusing particle whose value
does not affect the PDF at the large time scales of in-
terest associated with the diffusion problem. It must be
selected such that the ballistic time τm = m/α is much
smaller, but not necessarily negligible, compared to the
characteristic diffusion time. In one-dimensional multi-
layer systems, the ballistic time is set by the friction co-
efficient of the most viscous layer, and the inertial con-
vention for the average friction needs to be applied only
when the particle moves between layers. However, the
method can be readily implemented to diffusion problems
in higher dimensions and can, without any special diffi-
culty, be employed to study systems where the diffusion
coefficient changes continuously in space. Such problems
are generally more complicated for analytical treatment,
as well as for other computational approaches.
The model studied in this paper encompasses only two
aspects of pharmacokinetics in the DES system, namely
diffusion and crossing of a semi-permeable membrane.
More recent studies suggest that advection, caused by a
pressure gradient and blood circulation, and drug bind-
ing to receptor sites within the arterial wall may have a
substantial effect on the rate of drug transport [14]. Both
mechanisms can be dealt with within the underdamped
Langevin dynamics simulation method presented in this
work. Specifically, advection results from the action of a
deterministic (“regular”) force acting on the particle in
addition to friction and thermal noise. In the presence
force, the full form of G-JF discrete-time equations must
be used (see equations (21)-(22) in [35])
xn+1 = xn + bdtvn +
bdt
2m
βn+1 +
bdt2
2m
fn, (16)
vn+1 = avn +
b
m
βn+1 +
dt
2m
(
afn + fn+1
)
, (17)
which include appropriate additional terms missing in
equations (3) and (4). Drug binding can be dealt with by
distributing binding sites and introducing a short-range
attractive potential between the diffusing particle and
the binding sites. The forces associated with the gradi-
ent of the binding potentials can then be accounted for
via Eqs. (16) and (17). In a future publication we plan
to investigate model systems including these additional
effects, in order to demonstrate the great potential of
underdamped Langevin dynamics simulations for solving
non-trivial diffusion problems.
We conclude by restating that although this work deals
with the problem of drug diffusion from a DES, the larger
goal of the paper is to advocate underdamped Langeving
dynamics simulations as an efficient and simple to imple-
ment method for solving diffusion problems in heteroge-
neous environments. The method is based on computa-
tion of an ensemble of single particle stochastic trajecto-
ries with small time steps that are in the inertial regime.
This does not render the method useless for studying
problems where the time scales of interest are well in the
diffusive regime. Quite the contrary, if one is only in-
terested in diffusive behavior, the mass of the simulated
particles can be assigned a fictitious value (see details in
section IVB) to allow for faster simulations with larger
time steps.
We thank MD Carlos Cafri for helpful discussions
about physiological aspects of the problem.
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